Dr. Uhl is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
4940 Eastern Ave
Dept Of Neurology
Baltimore, MD 21224Phone+1 410-550-2843Fax+1 410-550-1535
Education & Training
Johns Hopkins UniversityResidency, Neurology, 1980 - 1983
Stanford Health Care-Sponsored Stanford UniversityInternship, Internal Medicine, 1979 - 1980- Johns Hopkins University School of MedicineClass of 1979
Certifications & Licensure
MD State Medical License 1979 - 2025- American Board of Psychiatry and Neurology Neurology
Awards, Honors, & Recognition
- Investigator Alumnus Howard Hughes Medical Institute, 1983
Clinical Trials
- Methylphenidate Studies for Drug Abuse Vulnerability Molecular Genentics Start of enrollment: 2004 Dec 22
- The Genetic Basis for Vulnerability to Substance Abuse Start of enrollment: 1992 Aug 01
- fMRI Study of Nicotinic Effect on Neurophysiology of Schizophrenia Start of enrollment: 2005 Feb 08
Publications & Presentations
PubMed
- Polygenic Risk for Substance Use Disorders as Predictors of Substance Use Initiation Among African American Youth.David W Sosnowski, Jill A Rabinowitz, Kenneth A Feder, Justin C Strickland, Dana B Hancock
Journal of Studies on Alcohol and Drugs. 2024-11-21 - Protein phosphatase 2A inhibitors: a possible pharmacotherapy for benzodiazepine dependence.Chisa Kobayashi, Nobue Kitanaka, Masanori Nakai, F Scott Hall, Kazuo Tomita
The Journal of Pharmacy and Pharmacology. 2024-11-15 - Opioid receptor antagonists reduce motivated wheel-running behavior in mice.Nobue Kitanaka, Kanayo Arai, Kaoko Takehara, F Scott Hall, Kazuo Tomita
Behavioural Pharmacology. 2024-04-01
Journal Articles
- Cocaine Reward Is Reduced by Decreased Expression of Receptor-Type Protein Tyrosine Phosphatase D (PTPRD) and by a Novel PTPRD AntagonistGeorge Uhl, MD, Proceedings of the National Academy of Sciences
Grant Support
- Understanding Addiction Vulnerability GenesNational Institute On Drug Abuse2009–2011
- Molecular Genetic Bases For Quit SuccessNational Institute On Drug Abuse2009–2011
- Genetic Approaches To Characterizing Drug Responses And Vulnerabilities: MiceNational Institute On Drug Abuse2009–2011
- Genetic Approaches To Characterizing Drug Responses And Vulnerabilities: HumansNational Institute On Drug Abuse2009–2011
- Molecular Genetic Bases For Quit SuccessNational Institute On Drug Abuse2007–2008
- Understanding Addiction Vulnerability GenesNational Institute On Drug Abuse2006–2008
- Genetic Approaches To Characterizing Drug Responses And Vulnerabilities: MiceNational Institute On Drug Abuse1998–2008
- Genetic Approaches To Characterizing Drug Responses And Vulnerabilities: HumansNational Institute On Drug Abuse1998–2008
- Dopamine Transporter--Structure/Function Studies Of Transporter And PromotersNational Institute On Drug Abuse2007
- Synaptic Vesicular Monamine TransporterNational Institute On Drug Abuse2000–2007
- MU Opiate ReceptorsNational Institute On Drug Abuse2000–2007
- Genetic Approaches To Characterizing Drug Responses AndNational Institute On Drug Abuse2002–2006
- Dopaminergic GenesNational Institute On Drug Abuse2002–2006
- Dopamine Transporter--Structure/Function Studies Of TranNational Institute On Drug Abuse2002–2006
- Genes Regulated By Abused DrugsNational Institute On Drug Abuse1997–2006
- Genetic Approaches To Characterizing Drug ResponsesNational Institute On Drug Abuse2005
- Dopamine Transporter--Structure/Function StudiesNational Institute On Drug Abuse2005
- Genetic Approaches To Characterizing Drug ResponsesNational Institute On Drug Abuse2004–2005
- Dopamine Transporter RegulationNational Institute On Drug Abuse2000–2005
- Synaptic Vesicular Monoamine TransporterNational Institute On Drug Abuse2004
- Dopamine Transporter-Human &Mouse Genes, Dopaminergic Disorders &Knockout MiceNational Institute On Drug Abuse1999–2000
- Dopamine Transporter--Structure/Function Studies Of Transporter And LigandsNational Institute On Drug Abuse1996–2000
- Mouse Synaptic Vesicular Monamine TransporterNational Institute On Drug Abuse1998–1999
- MU Opiate Receptors--Structure/Function And PhosphorylationNational Institute On Drug Abuse1997–1999
- Dopamine Transporter And Vesicular Monoamine TransporterNational Institute On Drug Abuse1997–1999
- Dopamine Transporter-Human &Amp;Mouse Genes, Dopaminergic Disorders &Amp;KnockoNational Institute On Drug Abuse1998
- Genetic Approaches To Characterizing Drug Responses And VulnerabilitiesNational Institute On Drug Abuse1997
- Dopamine Transporter--Human &Mouse Genes, Dopaminergic Disorders &Knockout MiceNational Institute On Drug Abuse1997
- Genetic Approaches To Characterizing Drug Responses And VulnerabilitiesNational Institute On Drug Abuse1996–1997
- Genes Regulated By Abused Drugs In Brain--Genes Involved In Neural SignalingNational Institute On Drug Abuse1996
- Dopamine Transporter--Cellular And Subcellular LocalizationNational Institute On Drug Abuse1996
- Dopamine Transporter I--Regulation By PhosphorylationNational Institute On Drug Abuse1996
- Dopamine Transporter-- Cellular And Subcellular LocalizationsNational Institute On Drug Abuse1995
- Neuroleptics/Dopamine-Co-Localized Peptide GenesNational Institute Of Mental Health1988–1990
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
